Board of Directors
George T. Rodeheaver, PhD, Founder and Chairman Board of Directors
Dr. Rodeheaver is the Richard F. Edlich Professor of Biomedical Research in
the Department of Plastic Surgery at the University of Virginia where he
founded and has directed the Wound Healing Research Lab for over 30 years.
He has co-authored 3 books, 33 chapters, and 228 scientific articles on the
science of wound care. He has also co-invented two effective wound care
products, which are patented. He was the first president of the National
Pressure Ulcer Advisory Panel and was a founding member of the Wound
Healing Society. He remains active in the Wound Healing Society, the American
Burn Association, and the Association for the Advancement of Wound Care. He
is recognized internationally as a wound care expert.
Adam J. Katz, MD, Founder, and Treasurer, Board of Directors
Dr. Katz is an Assistant Professor in the Department of Plastic Surgery, He also has an interest in, and experience with technology transfer and entrepreneurialism. He is
University of Virginia Health System. A graduate of Duke University, he
graduated in the top five of his class from the University of Michigan Medical
School and served as president of the National Honor Medical Society, AOA. As
a practicing board certified plastic surgeon, he treats complex wounds and
burns on a daily basis. He is currently the medical director of the Chronic Wound
Care Center at the University of Virginia. In addition to his clinical practice, Dr.
Katz directs an NIH-funded lab engaged in stem cell research and tissue repair.
the author of two issued and several pending patents, and he was a co-founder of StemSource,
Inc., a California company focused on stem cell storage and therapeutics. StemSource was a spin-
off of his research efforts at the University of Pittsburgh, and was bought by Macropore Biosurgery,
Inc. in 2002, now a part of Cytori Therapeutics (NASDAQ: CYTX).
James B. Farinholt, Senior Financial Advisor, Board of Directors
Mr. Farinholt has had an extensive career in both the private and public sectorsTechnology Transfer at VCU and continues to serve on the Board of Directors of the Intellectual
of finance and investment. Since 1992, he has been engaged in business
development at Virginia Commonwealth University as Special Assistant for
Economic Development to the President. During his promotion of
commercialization of scientific discoveries at the University, he co-founded Allos
Therapeutics, Inc. (NASDAQ: ALTH) a pharmaceutical start-up, which went public
in March 2000. In 1994 and 1995, Mr. Farinholt was Interim Director of
Properties Foundation of which he was a founding member. From 1996 through 1998, he was
Executive Director of the Virginia Biotechnology Research Park Authority where he oversaw the
development of the initial 257,000 square feet of office and laboratory facilities. Prior to joining
VCU, Mr. Farinholt had thirty years of experience in investment banking for small and medium-sized
businesses as an executive officer at The Chase Bank in New York, in Wheat First Union and
Galleher & Company in Richmond, Virginia. He is a partner at Whetstone Partners, LLC and Tall
Oaks Capital. Among Mr. Farinholt's directorships are: PharmaNetics, Inc. (NASDAQ: PHAR),
BioCache Pharmaceuticals, Inc., a privately owned bio-tech start-up and Owens & Minor, Inc.
(NYSE: OMI), the nation’s leading distributor of name-brand medical/surgical supplies, with annual
revenues in excess of $4 billion, where he is Chairman of the Audit Committee and a member of the
Executive and Strategic Planning Committees.
Neal G. Koller, President, CEO and Secretary, Board of Directors
Mr. Koller started his career with Wyeth Pharmaceuticals where he made within its first 2 years. He continues to serve the company as a member of its board of directors.
notable contributions over his 18 years with the company. Those achievements
include: General Manager for two different start-up divisions growing one to $
50M annualized revenues within 11 months of regulatory approvals and the
other to a 25% share in the US and launch in Europe within 18 months of
regulatory approvals; VP of a $ 120M Operating Room and Critical Care Division
where he doubled earnings within 3 years through 3 acquisitions, 1 divestiture
and introduction of a large portfolio of new products. Following Wyeth, Mr.
Koller joined as President WelCare Industries Spa, a European medical device
start-up company where he guided the company past its first $1M in revenues
Mr. Koller’s extensive startup responsibilities included: CEO of Sound Diagnostics, Inc., a spinout
company of Siemens AG, where he negotiated the first $5.6 million to launch the company and
Dovetail Technologies, Inc., where, as CEO and President, he raised the capital necessary to move
its second molecule into Phase I/II clinical trials. Mr. Koller comes to PluroGen after completing a
successful turnaround of the prestigious Bio/Pharmaceutical industry organization, the Parental
Drug Association, where he reversed revenue and profit decline in all four business units and
developed closer ties to US FDA, Europe’s EMEA and a number of national health authorities around
©2009 PluroGen Therapeutics, Inc.